BRONJBisphosphonate-Related Osteonecrosis of the Jaw (also seen as BROJ)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
(2016) studied the morphological differences of the mandible in 32 healthy individuals and 32 individuals with BRONJ on their panoramic radiographs and CBCT images.
made evaluations in their study by comparing mandibular changes between patients with BRONJ and healthy patients and found no difference between the groups in terms of the CA values.
Hyperostosis and BRONJ of the alveolar bone at lower left teeth 18 and 19 were suspected.
BRONJ is the most seen complication (66%) due to bisphosphonates usage.
The lack of a universal, accepted definition of bisphosphonate-related osteonecrosis of the jaw (BRONJ) has previously hindered recognition and reporting of the disease.
Histologic examination of the removed tissue showed osteonecrosis with chronic inflammatory changes in the periosteum, confirming the diagnosis of BRONJ. (Figure 2)
(12-14) However, more serious effects such as bisphosphonate-related osteonecrosis of jaw (BRONJ) is seen most commonly after intravenous NBPs such as pamidronate and zoledronate.
BRONJ affects cancer patients who get intravenous therapy, with a prevalence rate of up to 18.6% among multiple myeloma patients, 1.2%-12% among breast cancer patients, 6.5%-7% among prostate cancer patients and up to 0.1% among osteoporosis patients who take oral treatment.
This study tested the hypothesis that osteoporotic patients affected by BRONJ have a poorer dental and periodontal history than non-BRONJ patients, analysing them retrospectively, comparing medical and oral history and standardized radiographs.
Eufinger, "Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases," Clinical Oral Investigations, vol.